Clinical practice guidelines for the diagnosis and treatment of diffuse glioma-related epilepsy:2025 update - PubMed
3 hours ago
- #anti-seizure medications
- #clinical guidelines
- #glioma-related epilepsy
- Diffuse glioma-related epilepsy (dGRE) often presents with epilepsy as the initial symptom and is linked to tumor progression or recurrence.
- The pathogenesis of dGRE involves both peritumoral microenvironmental mechanisms and tumor-intrinsic factors.
- Diagnosis requires neuroimaging, EEG, molecular biomarkers, and spatial correlation between the tumor and epileptogenic zone.
- First-line therapy includes non-enzyme-inducing anti-seizure medications (ASMs) like levetiracetam and lacosamide; valproic acid is a second-line option.
- Surgical resection, especially maximal safe and supratotal removal guided by electrophysiological monitoring, improves seizure outcomes.
- Radiotherapy, chemotherapy, and targeted agents also contribute to seizure control.
- The 2025 Chinese clinical practice guidelines update ASM use, postoperative withdrawal strategies, and multidisciplinary treatment approaches.